Hour of Truth Approaching in CNS Pharmaceuticals (NASDAQ: CNSP) Testing of Drug Candidate Against Deadly Brain Cancer
A novel anthracycline believed to be effective in combatting deadly glioblastoma brain cancers by crossing the blood-brain barrier and zeroing in on the tumor will begin Phase 2 trials during Q1 of next yearThe drug, Berubicin, is being developed by CNS Pharmaceuticals after initial testing nearly 15 years ago resulted in improvements among some subjects, including one who has survived cancer-free since that timeThe company,…